3.20MMarket Cap-203P/E (TTM)
0.9950High0.8600Low37.50KVolume0.8600Open0.8601Pre Close34.89KTurnover1.30%Turnover RatioLossP/E (Static)3.27MShares17.400052wk High0.86P/B2.83MFloat Cap0.850052wk Low--Dividend TTM2.90MShs Float284.7980Historical High--Div YieldTTM15.70%Amplitude0.8500Historical Low0.9300Avg Price1Lot Size
Processa Pharmaceuticals Stock Forum
📊⚡️📊
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer | PCSA Stock News
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
• Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabine
• Results from this Phase 2 trial will evaluate NGC-Cap's safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer
Processa Pharmaceuticals : Ngc-Cap Phase 1B T - moomoo
Processa Pharmaceuticals Inc: Studies Support Potential Benefit as an Improved Treatment With Fewer Side Effects
https://www.moomoo.com/t/news/flash/19012294/fyryNQAmzb
No comment yet